Direct oral anticoagulants (DOACs) have changed the management of venous thromboembolism (VTE). In recent years their use has extended to the realm of cancer-associated VTE (CAT), but experts warn that a paucity of trial data in that setting should breed caution in the care of patients with haematological malignancies. “Given the escalated risk of VTE ...
Experts urge caution over paucity of trial data on DOACs in haematological malignancies
By Dave Levitan
1 Mar 2021